Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma
Authors:
- 26 February 2008
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 38 (5) , 847-856
Abstract
Summary: BackgroundIn a mouse model of mild chronic asthma, both inflammation and remodelling can be suppressed by dexamethasone (a glucocorticoid) and roflumilast (a selective phosphodiesterase‐4 inhibitor).ObjectiveTo better understand the underlying molecular mechanisms, we investigated the effects of treatment on airway expression of inflammation‐related cytokines, as well as on epithelial expression of growth factors.MethodsBALB/c mice systemically sensitized to ovalbumin were challenged with aerosolized antigen for 6 weeks and treated with roflumilast or dexamethasone during the final 2 weeks. Expression of mRNA, for a variety of cytokines and growth factors, was assessed in selectively dissected proximal airways or in airway epithelium obtained by laser capture microdissection.ResultsIn the airway wall of vehicle‐treated challenged animals, there was significantly elevated expression of mRNA for a variety of pro‐inflammatory and T helper type 2 cytokines, as well as for IFN‐γ. All these cytokines were suppressed by dexamethasone. Treatment with roflumilast reduced expression of IL‐17A, TNF‐α, granulocyte‐macrophage colony‐stimulating factor and IL‐6, but did not inhibit other cytokines. Both drugs suppressed the enhanced expression of mRNA for growth factors such as TGF‐β1 and FGF‐2 in airway epithelium.ConclusionsWhereas dexamethasone non‐specifically inhibits numerous mediators involved in inflammation and the immune response, roflumilast selectively inhibits a subset of pro‐inflammatory cytokines and growth factors. These mediators and/or the cells that produce them may have critical roles in the pathogenesis of the lesions of chronic asthma.Keywords
This publication has 49 references indexed in Scilit:
- Differentiation and function of Th17 T cellsCurrent Opinion in Immunology, 2007
- Building a better mouse model: experimental models of chronic asthmaClinical & Experimental Allergy, 2005
- The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalizationAnalytical Biochemistry, 2005
- Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactionsJournal of Allergy and Clinical Immunology, 2005
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Reassessing the Th2 cytokine basis of asthmaTrends in Pharmacological Sciences, 2004
- Expression of growth factors by airway epithelial cells in a model of chronic asthma: regulation and relationship to subepithelial fibrosisClinical & Experimental Allergy, 2004
- Dissociation of T helper type 2 cytokine‐dependent airway lesions from signal transducer and activator of transcription 6 signalling in experimental chronic asthmaClinical & Experimental Allergy, 2003
- Tumour necrosis factor alpha: a polcnlial mediator of asthmaClinical & Experimental Allergy, 1995
- Locally applied GM-CSF induces the accumulation of α-smooth muscle act in containing myofibroblastsVirchows Archiv B Cell Pathology Including Molecular Pathology, 1991